Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Biogen building
Biogen hopes to move from Phase I to Phase III with SMA candidate • Source: Shutterstock

Biogen is looking to improve the standard of care in spinal muscular atrophy with an aggressive development plan for Spinraza (nusinersen) follow-on salanersen (BIIB115), presenting Phase I data on June 25 at the SMA Research and Clinical Care meeting and outlining its goal to proceed directly from Phase I to a registrational Phase III program.

Key Takeaways
  • Biogen’s Phase I data for Spinraza follow-on salanersen shows ability to restore functioning SMN protein and reduce neurofilament levels, which may provide a disease-modifying effect.

Like Spinraza, salanersen is also an antisense oligonucleotide (ASO) therapy licensed from Ionis that acts to normalize production of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By 

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Novo Selects Internal CEO To Recharge Growth

 

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By 

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

More from R&D

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.

Pipeline Watch: Twelve Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.